Business Wire

Roswell Park Comprehensive Cancer Center Licenses Invivoscribe’s LymphoTrack Software for Plug and Play Pipeline Use

Share

Invivoscribe, Inc., a technology-driven international company focused on precision diagnostics with best-in-class products and services that optimize patient care and accelerate drug approvals worldwide, today announced licensing of key software and two new MRD clinical services.

“Clinical labs need to be able to analyze large amounts of clonality and MRD data quickly and easily. Current bioinformatics software generally requires that technicians click through software to analyze data one patient at a time; this is both tedious and prone to human errors. With such a large volume of patients samples we need to get from data to report as easily and accurately as possible,” says Dr. Sean Glenn of Roswell Park Comprehensive Cancer Center, New York.

Invivoscribe’s new pipeline LymphoTrack® Enterprise Software enables high volume customers to meet ever increasing testing demands. Laboratories require a high throughput platform that is both compliant with HIPAA requirements and provides seamless visualization to help interpret the raw data. They also want to be able to mine data from antigen receptor CDR3 regions. We’ve addressed both of these needs with the new pipeline software. The pipeline software for LymphoTrack on MiSeq® is available now with raw data access, CDR3 mining and reporting capabilities.

Tony Lialin, Chief Commercial Officer at Invivoscribe shared, “Software has been a hugely undervalued asset at Invivoscribe. We have developed tools for internal use that our customers would love to have access to in order to streamline their workflow and reduce bottlenecks in testing. This is a bioinformatics package we can commercialize to help support our partners, so we are doing just that.”

The new B-cell MRD Clonality and MyMRD-Myeloid Assays will be offered as LabPMM services using Illumina’s NextSeq® 550Dx and/or NovaSeq®. The release of these clinical services will rapidly follow the release of the LymphoTrack Enterprise Software. The new MRD services will be available for research studies in late 2021 and are slated for CAP/CLIA accreditation in early 2022.

With internationally standardized kits and services, custom assay development solutions, clinical trial management, regulatory expertise, and most recently, expanding availability and support for our bioinformatics analysis software, Invivoscribe continues to innovate to provide comprehensive support to our global partners.

About Invivoscribe

Invivoscribe has been Improving Lives with Precision Diagnostics® for more than twenty-five years, advancing the field of precision medicine by developing and selling standardized reagents, tests, and bioinformatics tools to more than 700 customers in 160 countries. Invivoscribe also has a significant impact on global health working with pharmaceutical companies to accelerate approvals of new drugs and treatments by supporting international clinical trials, developing, commercializing companion diagnostics, and providing expertise in both regulatory and laboratory services. With its proven ability to provide global access to distributable reagents, kits, and controls, as well as clinical trial services through our international clinical lab subsidiaries (LabPMM), Invivoscribe has demonstrated it is an ideal partner. For additional information please visit: www.invivoscribe.com or contact Invivoscribe at: customerservice@invivoscribe.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tony Lialin
inquiry@invivoscribe.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wipro Announces Co-innovation Space with Google Cloud17.9.2021 15:32:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the launch of the Wipro-Google Cloud Innovation Arena in Bangalore, India. This cloud collaboration space will provide in-house technical expertise, ensure seamless cloud adoption, and accelerate innovation to drive business transformation for customers. By combining the expertise and resources of Wipro FullStride Cloud Services and Google Cloud, this jointly developed innovation center will offer a unique combination of people, processes, and platforms that will collectively create a futuristic experience for customers globally. This state-of-the-art arena will showcase the talent, tools and best practices required to develop and deploy applications on Google Cloud. Jason Eichenholz, Senior Vice President, Global Head of Ecosystems & Partnerships, Wipro Limited said, “We are excited to strengthen our partnership with Google Clou

Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat17.9.2021 15:00:00 CEST | Press release

Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced today that ReVamp, an upcoming multiplayer social deception game, will launch soon in select markets exclusively for Snapchat. The vampire-themed game will be the first social deception title on Snapchat, giving Snapchatters their first chance to sink their teeth into this popular genre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005012/en/ Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat (Graphic: Business Wire) ReVamp is a real-time multiplayer imposter game where players aim to reveal who the vampire player is among their group of friends while they renovate the rooms of an old mansion. In the game, human players must complete renovation tasks, such as demolition and building, to improve their chances of survival while identifying and defeating the vampire during the voting phase. Vampire players mu

BeiGene Receives Positive CHMP Opinion for BRUKINSA ® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia17.9.2021 14:00:00 CEST | Press release

BeiGene (NASDAQ: BGNE; HKEX: 06160) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or first-line treatment for patients unsuitable for chemo-immunotherapy. “Bruton’s tyrosine kinase (BTK) inhibitors have emerged as a promising treatment for WM, yet treatment discontinuation due to lack of response or side effects remains a concern,” said Prof. Christian Buske, Medical Director at the University Hospital Ulm, Germany, and a trial investigator of the ASPEN study. “The ASPEN trial demonstrated that BRUKINSA provided deep and durable responses and offered substantial improvements in safety and tolerability over standard therapy. Patients in Europe with WM may soon have a new treatment option that can offer improved outcomes.

Janssen Receives Positive CHMP Opinion for BYANNLI ® (6-monthly Paliperidone Palmitate) for the Maintenance Treatment of Schizophrenia in Adults17.9.2021 12:50:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending the long-acting atypical antipsychotic therapy BYANNLI® (6-monthly paliperidone palmitate; PP6M) for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1-monthly paliperidone palmitate (PP1M)2 or 3-monthly paliperidone palmitate (PP3M).3 If approved by the European Commission, PP6M will provide the first twice-yearly treatment for adults living with schizophrenia and longest available dosing interval for an antipsychotic medication in the European Economic Area.1,4 “With only two injections per year, 6-monthly paliperidone palmitate has the potential to reduce the burden of taking medication frequently, giving eligible patients the opportunity to focus on other aspects of their life,” said Ludovic de Beaucoudrey, Ph.D., EMEA Therape

Henkel, Dow, Bayer, AB InBev, Zebra Technologies and Others to Chart Future of Supply Chain Visibility in Europe at FourKites Visibility 202117.9.2021 12:30:00 CEST | Press release

FourKites®, the world’s leading real-time supply chain visibility platform, today announced that its European customer conference, Visibility 2021, will be held virtually on 7 October. The theme of this year’s conference, “Go Beyond,” presents a bold vision for supply chains of the future, centered around automation, innovation and collaboration. Supply chain leaders from across Europe have the opportunity to network, share best practices and insights, and collaborate on FourKites’ product roadmap during the world’s largest virtual supply chain summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005213/en/ FourKites®, the world’s leading real-time supply chain visibility platform, today announced that its European customer conference, Visibility 2021, will be held virtually on 7 October. “FourKites' Visibility conference is exactly what the industry needs right now,” says Roy van der Heijden, Business Analyst at Int

Panasonic Completes Acquisition of Blue Yonder17.9.2021 09:00:00 CEST | Press release

Panasonic Corporation announced today that it has completed the acquisition of Blue Yonder, the leading end-to-end, digital fulfillment platform provider. Panasonic has now purchased the remaining 80% of shares of Blue Yonder, adding to the 20% which Panasonic acquired in July 2020. The investment values Blue Yonder at USD8.5 billion. Since Panasonic’s announcement to acquire all shares on April 23, 2021, the acquisition has completed antitrust clearance procedures and received approval of regulatory authorities in the U.S. and other countries. The acquisition accelerates Panasonic’s and Blue Yonder’s shared vision for an Autonomous Supply Chain™. By unifying Panasonic’s sensing technologies and edge devices with Blue Yonder’s AI/ML-powered planning, execution and commerce solutions, companies can create smarter and more connected e-commerce strategies, retail stores, warehouses, transportation, and workplaces. This unique end-to-end offering provides customers with unlimited visibilit

IFF Appoints Glenn Richter as Executive Vice President and Chief Financial Officer16.9.2021 22:15:00 CEST | Press release

IFF (NYSE: IFF) today announced that Glenn Richter, an accomplished financial executive with nearly three decades of experience overseeing finance and corporate strategy for multinational companies, has been appointed Executive Vice President and Chief Financial Officer, effective September 27, 2021. Mr. Richter was most recently Chief Financial Officer of TIAA, a leading global provider of financial services with $1.3 trillion in assets under management. He succeeds Rustom Jilla, who will be leaving the Company following a period of transition. With this appointment, Mr. Richter becomes a member of IFF’s Executive Committee and will be based in the Company’s New York City headquarters. “We are delighted to welcome Glenn to our leadership team. His experience leading large, global finance departments, implementing multi-year strategic productivity initiatives and managing transformative integrations will be a tremendous asset to our team,” said Andreas Fibig, Chairman and Chief Executi